Retraction Note: Psychopharmacology (2019) 236:2735–2745
10.1007/s00213-019-05249-5
The Editors have retracted this article after they were informed of protocol violations amounting to unethical conduct at the MP4 study site by researchers associated with this project. The authors have subsequently confirmed that they were aware of these violations at the time of submission of this article, but did not disclose this information to the journal or remove data generated by this site from their analysis. Additionally, the authors also did not fully declare a potential competing interest. Several of the authors are affiliated with either the Multidisciplinary Association for Psychedelic Studies (MAPS) or MAPS Public Benefit Corporation (MAPS PBC), a subsidiary that is wholly owned by MAPS. As is stated in the Funding declaration, MAPS fully funded and provided the MDMA that was used in this trial, and MAPS PBC organised the trial.
Allison A. Feduccia agrees with this retraction but disagrees with the wording of the retraction notice. Michael C. Mithoefer, Lisa Jerome, Anne Mithoefer, Mark Wagner, Berra Yazar-Klosinski, and Rick Doblin disagree with this retraction. Zach Walsh stated that they neither agree nor disagree with this retraction. The remaining authors did not respond to correspondence from the Publisher about this retraction.
Footnotes
The online version of the original article can be found at 10.1007/s00213-019-05249-5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.